Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
CAMBRIDGE, Mass., May 01, 2018 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 1:30 PM ET in Boston, MA.
A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
